Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen

Mendel A., Bernatsky S., Pineau C. A., St-Pierre Y., HANLY J. G., Urowitz M. B., ...Daha Fazla

RHEUMATOLOGY, cilt.58, sa.7, ss.1259-1267, 2019 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 58 Sayı: 7
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1093/rheumatology/kez014
  • Dergi Adı: RHEUMATOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1259-1267
  • Anahtar Kelimeler: systemic lupus erythematosus, anti-phospholipid syndrome, contraception, epidemiology, COMBINED ORAL-CONTRACEPTIVES, VENOUS THROMBOSIS, ANTIPHOSPHOLIPID ANTIBODIES, NEUROPSYCHIATRIC EVENTS, PREGNANCY OUTCOMES, RISK, DIAGNOSIS, CRITERIA, CLASSIFICATION, CANCER
  • İstanbul Üniversitesi Adresli: Evet

Özet

Objectives To assess the prevalence of combined hormonal contraceptives (CHCs) in reproductive-age women with SLE with and without possible contraindications and to determine factors associated with their use in the presence of possible contraindications.